Vivos Therapeutics Acquires 11% Stake in SOD Sciences

• Vivos Therapeutics closed the acquisition of an 11% fully diluted stake in SOD Sciences and 50% ownership of its pseudohypoxia test.
• Consideration comprised 12,000 Series C Convertible Preferred Stock shares with $12 million aggregate stated value; no cash changed hands.
• The preferred stock converts at $0.15 into up to 80,000,000 common shares, subject to a 19.99% exchange cap pending stockholder approval.
• The test interest entitles Vivos to 50% of contribution margin on test sales through either company's channels.
• The transaction is expected to add $10.38 million to stockholders' equity, potentially restoring compliance with Nasdaq's $2.5 million minimum requirement.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Vivos Therapeutics Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001493152-26-047601), on October 19, 2026, and is solely responsible for the information contained therein.